CD8A and neoplasm: Finally, in a highly significant paper in 2018 this group obtained evidence that tumor-reactive CD8(+) T cells can be liberated from tumor-induced immunosuppression by A2AR antagonists and by A2AR but not A2BR gene deletion (18).